Table 4.
Effect of l-arginine on variables derived from an OGTT
| Variable | Europid (n = 10) | South Asian (n = 10) | ||
|---|---|---|---|---|
| Placebo | l-Arginine | Placebo | l-Arginine | |
| Peak glucose (mmol/l) | 10.7 ± 0.6 | 10.1 ± 0.5 | 9.4 ± 0.5 | 9.1 ± 0.5††† |
| Peak glucose time (min) | 62.0 ± 9.2 | 51.0 ± 5.7 | 44.0 ± 4.0 | 52.0 ± 5.1†† |
| AUC0–120 glucose (mmol/l × min) | 1052 ± 64 | 955 ± 47** | 922 ± 57 | 921 ± 51 |
| AUC0–120 incremental glucose (mmol/l × min) | 382 ± 56 | 288 ± 33* | 281 ± 45 | 278 ± 40 |
| Peak insulin (pmol/l) | 1479 ± 242 | 1096 ± 151* | 1683 ± 389 | 1508 ± 277 |
| Peak insulin time (min) | 73 ± 10 | 60 ± 8 | 71 ± 9 | 70 ± 7 |
| AUC0–120 insulin (pmol/l × min) | 114,240 ± 19,046 | 87,514 ± 13,109* | 142,012 ± 37,842 | 126,609 ± 25,157 |
| AUC120 incremental insulin (pmol/l × min) | 100,223 ± 17,397 | 72,415 ± 11,008* | 125,077 ± 34,058 | 111,052 ± 22,492 |
| Matsuda index | 2.27 ± 0.37 | 2.56 ± 0.41‡ | 2.13 ± 0.30†† | 2.22 ± 0.33 |
| HOMA-IR | 4.21 ± 0.62 | 4.56 ± 0.81 | 4.92 ± 1.25 | 4.49 ± 0.88 |
| IGI (pmol/mmol) | 232 ± 45 | 224 ± 40 | 350 ± 78 | 388 ± 76 |
| DIo | 1.9 ± 0.2 | 1.9 ± 0.4 | 2.8 ± 0.6 | 3.5 ± 0.8 |
Values are presented as mean ± SEM
*p < 0.05 and **p < 0.01, l-arginine vs placebo; ††p < 0.01 and †††p < 0.001, Europid vs South Asian; ‡p = 0.06, l-arginine vs placebo